AiRuiKa (camrelizumab) / CG Invites, Jiangsu Hengrui Pharma, HLB Bio Group, NPO Petrovax - LARVOL DELTA

Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial (clinicaltrials.gov) - P2 | N=208 | Recruiting | Sponsor: Ming-Yuan Chen

New P2 trial • Head and Neck Cancer • Nasopharyngeal Carcinoma • Oncology • Solid Tumor

Camrelizumab plus sorafenib or apatinib achieved long-term survival in a patient with hepatocellular carcinoma and an Eastern Cooperative Oncology Group performance status of 3: a case report. (PubMed, J Gastrointest Oncol) - "Treatment adherence was complicated by financial interruptions but resumed with a combination of apatinib plus camrelizumab. This case may provide preliminary support for the potential use of targeted therapy combined with immune checkpoint inhibitors in patients with HCC and an ECOG performance status of 3."

IO biomarker • Journal • Cardiovascular • Hematological Disorders • Hepatitis B • Hepatocellular Cancer • Infectious Disease • Oncology • Solid Tumor • Thrombosis • AFP

Adjuvant Immunotherapy for Esophageal Squamous Cell Carcinoma (clinicaltrials.gov) - P=N/A | N=98 | Not yet recruiting | Sponsor: Sichuan University

New trial • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Oncology • Squamous Cell Carcinoma

Efficacy and Safety of Hepatic Artery Infusion Chemotherapy Combined with Donafenib and Camrelizumab in the Treatment of Patients with Unresectable Hepatocellular Carcinoma: A Retrospective, Single-Arm Study. (PubMed, J Hepatocell Carcinoma) - "To evaluate the efficacy and safety of hepatic artery infusion chemotherapy with oxaliplatin, fluorouracil, and leucovorin (FOLFOX-HAIC) combined with donafenib and camrelizumab in patients with unresectable hepatocellular carcinoma (uHCC). Grade 3 or higher TRAEs were observed in 61.2% of patients. For patients with uHCC, the combination therapy of FOLFOX-HAIC with donafenib and camrelizumab demonstrates favorable efficacy and manageable adverse events."

Journal • Retrospective data • Hepatocellular Cancer • Oncology • Solid Tumor

Long-term survival in advanced pulmonary large-cell neuroendocrine carcinoma after multi-line immunochemotherapy and anti-angiogenic therapy: a case report. (PubMed, Front Immunol) - "This report presents the case of a 45-year-old Chinese woman with advanced PLCNEC who received first-line treatment with a four-drug regimen consisting of etoposide, cisplatin, camrelizumab, and endostar...Second-line therapy with atezolizumab, bevacizumab, and docetaxel achieved a PFS2 of 1 year. Third-line treatment maintained atezolizumab and introduced the anti-angiogenic agent anlotinib and chemotherapeutic agent pemetrexed, resulting in a PFS3 of 6 months...This case illustrates the potential for long-term survival in advanced PLCNEC through intensive, multi-line combination therapies. The favorable outcome observed in this patient supports further investigation of such combination strategies in clinical studies."

Journal • Endocrine Cancer • Lung Cancer • Neuroendocrine Carcinoma • Neuroendocrine Tumor • Non Small Cell Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

Camrelizumab plus SOX chemotherapy as adjuvant therapy for pathological stage III gastric or gastroesophageal junction adenocarcinoma: a prospective, multicenter, single-arm, phase II trial. (PubMed, Ther Adv Med Oncol) - P2 | "Patients with pStage III G/GEJ adenocarcinoma were enrolled, receiving camrelizumab (200 mg), followed by oxaliplatin (130 mg/m2), both administered on day 1 of each 21-day cycle, and tegafur-gimeracil-oteracil potassium capsules (40-60 mg, twice daily) for 2 weeks, followed by a 7-day rest period. However, careful patient selection is necessary to identify patients most likely to benefit from combination therapy. ClinicalTrials.gov registry: NCT04515615; Date of registration: August 14, 2020; Weblink: https://clinicaltrials.gov/study/NCT04515615."

Journal • P2 data • Endocrine Disorders • Esophageal Cancer • Gastric Adenocarcinoma • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Hematological Disorders • Infectious Disease • Interstitial Lung Disease • Leukopenia • Neutropenia • Oncology • Pneumonia • Respiratory Diseases • Solid Tumor • Thrombocytopenia

Efficacy and Safety of Super-hyperfractionation Pulse Radiotherapy Combined With ICIs for Advanced NSCLC (clinicaltrials.gov) - P=N/A | N=40 | Recruiting | Sponsor: Xinqiao Hospital of Chongqing | Trial completion date: Mar 2025 ➔ Mar 2026 | Trial primary completion date: Mar 2025 ➔ Mar 2026

Checkpoint inhibition • Trial completion date • Trial primary completion date • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Focus on PD-1/PD-L1-Targeting Antibodies in Colorectal Cancer: Are There Options Beyond Dostarlimab, Nivolumab, and Pembrolizumab? A Comprehensive Review. (PubMed, Molecules) - "However, a growing number of additional PD-1/PD-L1 inhibitors, including AMP-224, atezolizumab, avelumab, camrelizumab, durvalumab, envafolimab, sintilimab, spartalizumab, tislelizumab, and toripalimab, are currently under investigation, offering new possibilities for the expansion of treatment options...Additionally, it explores key challenges such as primary and acquired resistance, limited efficacy in microsatellite-stable (MSS) CRC, and the complexities of combination strategies aimed at enhancing immunotherapeutic responses. By addressing these obstacles and highlighting prospects, this review provides insights into the evolving landscape of PD-1/PD-L1-targeted therapies in CRC and their potential to improve patient outcomes."

Journal • Review • Colorectal Cancer • Oncology • Solid Tumor • MSI

Comparative Efficacy of PD-1 Inhibitor-Based Neoadjuvant Chemoimmunotherapy Regimens for Resectable Stage II-IIIa NSCLC: A Real-World Retrospective Study. (PubMed, Thorac Cancer) - "All treatment regimens elicited substantial pathological responses and exhibited acceptable safety profiles. Pembrolizumab and tislelizumab were associated with better OS and lower toxicity, supporting their preferential use in neoadjuvant therapy for resectable NSCLC."

Clinical • Journal • Real-world evidence • Retrospective data • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

The safety and effectiveness of sintilimab versus camrelizumab, both plus targeted drugs, in advanced hepatocellular carcinoma. (PubMed, Front Immunol) - "Sintilimab and camrelizumab, both plus targeted agents, have equal clinical effectiveness and incidences of AEs. The effectiveness of sintilimab-lenvatinib and camrelizumab-apatinib are similar in first-line treatment of advanced HCC, despite a slight superiority in sintilimab-lenvatinib is observed."

Clinical • Journal • Retrospective data • Hepatocellular Cancer • Oncology • Solid Tumor

Updated Network Meta-Analysis of First-Line Systemic Treatments for Advanced HCC: Consistent Role of TACE. (PubMed, Liver Cancer) - "Transarterial chemoembolization (TACE) combined with lenvatinib provided the greatest improvement in OS over sorafenib, with a hazard ratio of 0.41 (95% confidence interval, 0.30-0.58), followed by sintilimab + IBI305 (0.57; 0.43-0.75), camrelizumab + rivoceranib (0.62; 0.48-0.80), atezolizumab + bevacizumab (0.66; 0.51-0.85), lenvatinib + pembrolizumab (0.77; 0.62-0.97), and tremelimumab + durvalumab (0.78; 0.64-0.95). For advanced HCC, our first-line analysis consistently scored TACE + lenvatinib the best for survival outcomes, followed by various immunotherapy-based combinations. However, the superior efficacy of TACE + lenvatinib should be interpreted with consideration of its derivation from a region with high hepatitis B virus prevalence."

Journal • Retrospective data • Review • Hepatitis B • Hepatocellular Cancer • Infectious Disease • Liver Cancer • Oncology • Solid Tumor

Union-mRC: Short Course Radiotherapy Followed by CAPOX and Carrilizumab and Bevacizumab or Cetuximab for the Initial Treatment of Unresectable Metastatic Rectal Cancer (clinicaltrials.gov) - P2 | N=80 | Not yet recruiting | Sponsor: Wuhan Union Hospital, China

New P2 trial • Colorectal Cancer • Oncology • Rectal Cancer • Solid Tumor

Neoadjuvant chemoradiotherapy with or without PD-1/PD-L1 inhibitors in locally advanced rectal cancer: a systematic review and meta-analysis. (PubMed, BMC Cancer) - "The addition of PD-1 inhibitors to neoadjuvant CRT significantly improves pCR rates in LARC without increasing toxicity. These findings support their potential role in standard treatment protocols, warranting further phase III trials."

Clinical • Journal • Retrospective data • Review • Colorectal Cancer • Oncology • Rectal Cancer • Solid Tumor

Adjuvant Chemoradiation and Immunotherapy for Extrahepatic Cholangiocarcinoma and Gallbladder Cancer: A Randomized Clinical Trial. (PubMed, JAMA Oncol) - P2 | "The observed camrelizumab plus concurrent capecitabine and radiotherapy efficacy warrants further study with active treatment (chemotherapy or chemoradiation therapy) as the control group. ClinicalTrials.gov Identifier: NCT04333927."

Clinical • Journal • Biliary Cancer • Biliary Tract Cancer • Cholangiocarcinoma • Gallbladder Cancer • Oncology • Solid Tumor

Camrelizumab in Combination With Apatinib in Patients With Radioactive Iodine-refractory Differentiated Thyroid Cancer (clinicaltrials.gov) - P2 | N=20 | Active, not recruiting | Sponsor: Peking Union Medical College Hospital | Recruiting ➔ Active, not recruiting | Trial completion date: Dec 2024 ➔ Dec 2025 | Trial primary completion date: Dec 2023 ➔ Dec 2025

Enrollment closed • Trial completion date • Trial primary completion date • Endocrine Cancer • Oncology • Solid Tumor • Thyroid Gland Carcinoma • Thyroid Gland Papillary Carcinoma

EFFICACY AND SAFETY OF CAMRELIZUMAB IN ESOPHAGEAL SQUAMOUS CELL CARCINOMA: A SYSTEMATIC REVIEW AND META-ANALYSIS' (UEGW 2025) - No abstract available

Retrospective data • Review • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Oncology • Squamous Cell Carcinoma

Involved-field Radiotherapy-TNT Combined With PD-1 Inhibitor for pMMR Locally Advanced Rectal Cancer (Neo-Field I) (clinicaltrials.gov) - P2 | N=162 | Recruiting | Sponsor: Hebei Medical University Fourth Hospital

New P2 trial • pMMR • Colorectal Cancer • Oncology • Rectal Cancer • Solid Tumor

Association of alpha-fetoprotein (AFP) and clinical outcomes in patients with unresectable hepatocellular carcinoma (uHCC) treated with camrelizumab + rivoceranib vs sorafenib (CARES-310) (ESMO-GI 2025) - P3 | "These results suggest meaningful clinical benefit of cam + rivo as first-line therapy for uHCC compared to sor regardless of baseline AFP level or etiology."

Clinical • Clinical data • Hepatocellular Cancer • Oncology • Solid Tumor • AFP • FLT1

Transarterial chemoembolization (TACE) with or without anti-PD1/PD-L1 systemic therapy in unresectable hepatocellular carcinoma: A meta-analysis of randomized clinical trials (ESMO-GI 2025) - "PD1/PD-L1 agents (camrelizumab, durvalumab, or pembrolizumab) arms included anti-angiogenic agents (TKIs or bevacizumab) in combination with immunotherapy. This meta-analysis demonstrates the significant efficacy of TACE combined with immunotherapy in patients with unresectable HCC. Further data from ongoing studies with extended follow-up are necessary to assess the long-term benefits and safety of this combination approach."

Retrospective data • Hepatocellular Cancer • Oncology • Solid Tumor

Reactive cutaneous capillary endothelial proliferation in esophageal squamous cell carcinoma patients treated with camrelizumab-based therapy: A pooled analysis of two phase III trials (ESMO-GI 2025) - P3 | "RCCEP is a common but manageable irAE in patients receiving camrelizumab-based therapy. Its occurrence correlates with improved outcomes, suggesting RCCEP as a potential biomarker for predicting treatment response and survival in advanced ESCC. These findings offer insights for patient management and treatment optimization."

P3 data • Retrospective data • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Oncology

Efficacy of Argon-Helium Cryoablation Plus PD-1 Inhibitors in NSCLC (clinicaltrials.gov) - P=N/A | N=60 | Completed | Sponsor: The First Hospital of Hebei Medical University

New trial • Lung Cancer • Lung Non-Small Cell Squamous Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Patient Derived Organoids (PDOs) to Observe the Clinical Consistency of Personalized Neoadjuvant Therapy for Resectable Esophageal Squamous Cell Carcinoma (clinicaltrials.gov) - P=N/A | N=30 | Recruiting | Sponsor: Shanghai Zhongshan Hospital

New trial • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Oncology • Squamous Cell Carcinoma

Induction-Concurrent Chemoradiotherapy with or without Camrelizumab for Postoperative Residual High-Grade Gliomas: An Open, Randomized, Phase II Clinical Study (ASTRO 2025) - No abstract available

Clinical • P2 data • Brain Cancer • Glioma • High Grade Glioma • Solid Tumor

Efficacy and Safety of Camrelizumab and Apatinib in Combination with IMRT in Unresectable Hepatocellular Carcinoma: A Non-Randomised Phase 2 Study (ASTRO 2025) - No abstract available

Clinical • Combination therapy • P2 data • Hepatocellular Cancer • Oncology • Solid Tumor

Case Report: Durable complete response of advanced-stage hepatocellular carcinoma to DEB-TACE combined with lenvatinib and camrelizumab. (PubMed, Front Immunol) - "Initially, he received apatinib in combination with camrelizumab; however, due to intolerance to apatinib's side effects, the regimen was adjusted to lenvatinib and camrelizumab. The combination of DEB-TACE, lenvatinib, and camrelizumab demonstrated efficacy in a patient with advanced HCC and lung metastases. These findings suggest that integrating MKIs and ICIs may represent a potential treatment approach for select advanced HCC cases, warranting further validation in larger studies."

Journal • Fibrosis • Gastroenterology • Hepatitis B • Hepatocellular Cancer • Hepatology • Immunology • Infectious Disease • Liver Cirrhosis • Oncology • Solid Tumor